2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
70
Carcinoma, Hepatocellular
25
Prostatic Neoplasms
21
Neoplasm Metastasis
19
Neoplasms
17
Carcinoma, Non-Small-Cell Lung
16
Kidney Neoplasms
14
Osteosarcoma
9
Neuroendocrine Tumors
9
Carcinoma, Transitional Cell
9
Carcinoma, Medullary
9
Sarcoma
8
Colorectal Neoplasms
8
Urinary Bladder Neoplasms
7
Sarcoma, Ewing
7
Melanoma
7
Breast Neoplasms
7
Brain Neoplasms
7
Thyroid Neoplasms
6
Ovarian Neoplasms
6
Clear-cell metastatic renal cell carcinoma
6
Recurrence
5
Pancreatic Neoplasms
5
Lung Neoplasms
5
Carcinoma
5
Urethral Neoplasms
4
Triple Negative Breast Neoplasms
4
Multiple Myeloma
4
Liver Neoplasms
4
Thyroid Cancer, Papillary
3
Interventions
Abiraterone Acetate
7
enzalutamide
6
olaparib
5
Prednisone
5
Pluvicto
5
Docetaxel
5
radium Ra 223 dichloride
4
darolutamide
4
cabazitaxel
3
Prednisolone
3
testosterone 17 beta-cypionate
2
fludarabine
2
abiraterone
2
Nivolumab
2
Cyclophosphamide
2
Androgen Antagonists
2
sipuleucel-T
1
rucaparib
1
poly ICLC
1
pamiparib
1
niraparib
1
lactitol
1
fludarabine phosphate
1
fluciclovine F-18
1
enfortumab vedotin
1
ebastine
1
copanlisib
1
cabozantinib
1
bempegaldesleukin
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer
×
cabozantinib
×
Clear all
NCT05613894
2025-10-31
CaboLu
University of Utah
Phase 1
Recruiting
33 enrolled